Mumbai hospital staffer likely facing new charges in man's MRI-related death

Police investigating the death of 32-year-old Rajesh Maru—who was sucked into an MRI machine at Nair Hospital in Mumbai, India, in January—are expected to bring new charges against Nair employee Vitthal Chavan, 35, for Maru’s death after allowing him to enter the MRI room with a metallic oxygen cylinder, according to a Nov. 5 report by The Times of India.

Trulicity® (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes

INDIANAPOLIS, November 5, 2018 – Trulicity® (dulaglutide) significantly reduced major adverse cardiovascular events (MACE), a composite endpoint of cardiovascular (CV) death, non-fatal myocardial infarction (heart attack) or non-fatal stroke, meeting the primary efficacy objective in the precedent-setting REWIND trial.

Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors in people with type 2 diabetes with and without cardiovascular disease

Ridgefield, Conn. and Indianapolis, November 5, 2018 — Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed Jardiance® was associated with a 44 percent relative risk reduction in hospitalization for heart failure (HHF) compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in routine clinical practice in the U.S.

Skeptics worry heart drug is overhyped based on limited info

Biopharmaceutical company Amarin announced top-line results for its purified eicosapentaenoic acid (EPA) product in September, hailing the 25 percent risk reduction in a composite of cardiovascular outcomes associated with icosapent ethyl (Vascepa). But critics who commented on the results to Kaiser Health News worried the excitement over the trial is premature.